LambdaVision Announces First Closing of Seed Round to Advance Artificial Retina Preclinical Studies for Retinal Eye Diseases

FARMINGTON, Conn.--(BUSINESS WIRE)--LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund, a fund spun out of MIT. The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures. The targeted raise will fund LambdaVision’s GMP manufacturing scale up a